interaction records 54 assistance programs 55 0 personal data stored

Drug data · Schedule IV · shortage, price, volume

Clonazepam tablets: 43 months on the FDA shortage list while the generic benchmark price fell 22% since 2021

The FDA says supply is short. The pharmacy benchmark says the generic tablet now costs $0.025 each, against $0.025 in 2013. Both are true, and they measure different things: availability on one side, the average price pharmacies pay on the other.

FDA shortage list, 2026-10-27NADAC, October 2026Medicaid SDUDinferred monthno data
  1. The tablet has been on the FDA list continuously since April 2023, 43 months.
  2. Only 24% of shortage listings since 2014 have lasted this long. The median listing lasts 20 months.
  3. A generic 1 mg tablet costs pharmacies $0.025 on the NADAC benchmark in October 2026, 22% below its 2021 median.
  4. The brand Klonopin tablet is $3.05 each, about 125 times the generic.
  5. Medicaid paid for 879,834 tablet prescriptions in Q4 2025, 12% fewer than in Q4 2021. Fills fell across a stretch in which the tablet was listed as short in 43 of 43 months.

Not medical advice. This page reports public records about supply and pharmacy cost. Ask a pharmacist or prescriber about your own medication.

Three clocks on one timeline

Each lane uses the same monthly axis, so you can read across: when the FDA listed the tablet, what pharmacies were paying, and how many Medicaid prescriptions were filled.

on the listinferred across a missing captureno capture or no price$ per tabletprescriptionspreliminary quarter

Swipe the chart sideways to see all 14 years.

Three clocks: FDA shortage list, pharmacy acquisition cost and Medicaid prescriptionsShared monthly timeline. Top lane: months the tablet was on the FDA shortage list. Middle lane: NADAC price per tablet by strength. Bottom lane: Medicaid prescriptions per quarter. 2014201520162017201820192020202120222023202420252026FDA shortage listtablet, by name2013-01 to 2014-05: no capture of the FDA list for these months2014-09 to 2014-09: no capture of the FDA list for these months2016-02 to 2016-02: no capture of the FDA list for these months2018-10 to 2018-11: no capture of the FDA list for these months2019-02 to 2019-04: no capture of the FDA list for these months2023-04 to 2024-09: on the list (observed)2024-10 to 2025-08: on the list (inferred across a missing capture)2025-09 to 2026-10: on the list (observed)first listed Apr 2023Pharmacy costNADAC, $ per tabletbold = 1 mg generic$0$0.03$0.06$0.025 in 2013$0.025 nowMedicaid fillsprescriptions per quartertablet2013Q1: 211,780 prescriptions; unsuppressed state rows only2013Q2: 212,495 prescriptions; unsuppressed state rows only2013Q3: 183,767 prescriptions; unsuppressed state rows only2013Q4: 171,686 prescriptions; unsuppressed state rows only2014Q1: 161,053 prescriptions; unsuppressed state rows only2014Q2: 175,094 prescriptions; unsuppressed state rows only2014Q3: 173,912 prescriptions; unsuppressed state rows only2014Q4: 142,590 prescriptions; unsuppressed state rows only2015Q1: 129,164 prescriptions; unsuppressed state rows only2015Q2: 142,005 prescriptions; unsuppressed state rows only2015Q3: 185,499 prescriptions; unsuppressed state rows only2015Q4: 281,080 prescriptions; unsuppressed state rows only2016Q1: 350,315 prescriptions; unsuppressed state rows only2016Q2: 368,717 prescriptions; unsuppressed state rows only2016Q3: 377,695 prescriptions; unsuppressed state rows only2016Q4: 413,300 prescriptions; unsuppressed state rows only2017Q1: 386,241 prescriptions; unsuppressed state rows only2017Q2: 446,226 prescriptions; unsuppressed state rows only2017Q3: 439,778 prescriptions; unsuppressed state rows only2017Q4: 369,044 prescriptions; unsuppressed state rows only2018Q1: 495,717 prescriptions; unsuppressed state rows only2018Q2: 623,322 prescriptions; unsuppressed state rows only2018Q3: 596,154 prescriptions; unsuppressed state rows only2018Q4: 750,593 prescriptions; unsuppressed state rows only2019Q1: 723,259 prescriptions; unsuppressed state rows only2019Q2: 719,176 prescriptions; unsuppressed state rows only2019Q3: 739,176 prescriptions; unsuppressed state rows only2019Q4: 872,603 prescriptions; unsuppressed state rows only2020Q1: 930,820 prescriptions; unsuppressed state rows only2020Q2: 967,601 prescriptions; unsuppressed state rows only2020Q3: 1,030,376 prescriptions; unsuppressed state rows only2020Q4: 1,023,922 prescriptions; unsuppressed state rows only2021Q1: 1,008,976 prescriptions; unsuppressed state rows only2021Q2: 1,023,121 prescriptions; unsuppressed state rows only2021Q3: 1,017,671 prescriptions; unsuppressed state rows only2021Q4: 1,000,946 prescriptions; unsuppressed state rows only2022Q1: 979,478 prescriptions; unsuppressed state rows only2022Q2: 987,752 prescriptions; unsuppressed state rows only2022Q3: 1,004,693 prescriptions; unsuppressed state rows only2022Q4: 974,269 prescriptions; unsuppressed state rows only2023Q1: 1,032,633 prescriptions; unsuppressed state rows only2023Q2: 1,003,096 prescriptions; unsuppressed state rows only2023Q3: 1,000,989 prescriptions; unsuppressed state rows only2023Q4: 940,815 prescriptions; unsuppressed state rows only2024Q1: 939,925 prescriptions; unsuppressed state rows only2024Q2: 924,115 prescriptions; unsuppressed state rows only2024Q3: 950,866 prescriptions; unsuppressed state rows only2024Q4: 901,511 prescriptions; unsuppressed state rows only2025Q1: 902,020 prescriptions; unsuppressed state rows only2025Q2: 884,876 prescriptions; unsuppressed state rows only2025Q3: 896,259 prescriptions; unsuppressed state rows only2025Q4: 879,834 prescriptions; unsuppressed state rows only2026Q1: 789,960 prescriptions (latest quarter, preliminary: CMS may revise); unsuppressed state rows only1.0M0
Top: months the tablet name was on the FDA list (Wayback captures of the FDA page; the current FDA record says posted 2023-03-10). Middle: NADAC per tablet, one line per strength. Bottom: Medicaid prescriptions per quarter. Medicaid volume: 103,366 rows pulled for this drug, 29,266 (28%) suppressed by CMS for small cells and left out, never counted as zero, so every bar is a floor; state XX national rows excluded; the hatched latest quarter is preliminary. Fills also move with Medicaid enrollment, so a change is not by itself evidence of a shortage.

How long do shortages last?

Each step is a drop in the share of FDA shortage listings still running. The dot is this drug.

Share of FDA shortage listings still running after N months, with this drug marked0%25%50%75%100%024487296120months on the FDA listmedian 20 monthsthis listing: 43 mo24% lasted this long
Kaplan-Meier on 430 listings, 2014 to 2026, by ingredient. 18 months have no capture and are bridged by inference.

What a pharmacy pays per unit

NADAC is the average price retail pharmacies pay, per tablet.

Pharmacy acquisition cost per unit, brand against genericBrand tablet (Klonopin 1 mg)$3.05Generic tablet (1 mg, median)$0.025
Thirty generic 1 mg tablets is about $0.735 at this benchmark. It is acquisition cost, not a retail price.

Which forms are short

FDA listing by dosage form
FormListed nowMonths listedFDA records (2026-10-27)
tabletYes, since April 2023431 unavailable, 39 available (40 records)
ODTNo0none

Price by strength

Tablet: generic acquisition cost per tablet by strength
StrengthNow2021 medianFirst monthNow vs 2021HistoryNDCs
0.125 mg$0.499$0.649$0.7762013-11-23%2
0.5 mg$0.020$0.026$0.0162013-11-24%22
1 mg$0.025$0.031$0.0252013-11-22%24
2 mg$0.040$0.037$0.0392013-11+7%15
Tablet: brand (Klonopin) acquisition cost per tablet by strength
StrengthNow2021 medianFirst monthNow vs 2021HistoryNDCs
0.5 mg$2.68n/a$2.442022-02n/a1 (single product, not a median)
1 mg$3.05n/a$2.792022-02n/a1 (single product, not a median)
ODT: generic acquisition cost per tablet by strength (not on the FDA list)
StrengthNow2021 medianFirst monthNow vs 2021HistoryNDCs
0.125 mg$0.499$0.649$0.6292019-11-23%3
0.25 mg$0.429$0.713$0.7252013-11-40%5
0.5 mg$0.527$0.659$0.5872019-11-20%3
1 mg$0.543$0.762$0.6142019-11-29%3
2 mg$0.896$1.26$1.072013-11-29%5
Read the price with care. NADAC is a national survey average of retail pharmacy invoices. It is not a quote, not what any patient paid, and it excludes discounts and rebates. A flat or falling benchmark during a shortage means pharmacies' average invoice cost did not rise, not that every patient could find the drug at that price.
FDA caution. The FDA drug shortage list is updated as manufacturers report and should not be relied on for medical care. Ask a pharmacist or prescriber about supply.

Questions

Is Clonazepam still in shortage?

On the FDA list as of 2026-10-27, the tablet is listed under 40 presentations: 1 unavailable, 0 with limited availability and 39 available. It has been continuously listed since April 2023. FDA says not to rely on the list for medical care; ask a pharmacist.

Did the shortage raise the pharmacy price?

Not in the benchmark. The NADAC survey average for a generic 1 mg tablet is $0.025 in October 2026, 22% below its 2021 median and 4% below November 2013. NADAC is a national average of retail pharmacy invoices, so it measures what pharmacies pay on average, not what any one patient was charged.

Did Medicaid fills fall during the shortage?

Yes. CMS State Drug Utilization Data shows 879,834 Medicaid-paid tablet prescriptions in Q4 2025, 12% fewer than in Q4 2021 (1,000,946). Those counts are a floor because CMS suppresses small cells, they cover Medicaid only and move with Medicaid enrollment, and they count prescriptions that were filled, not demand that went unmet. A change in fills is not by itself evidence of a shortage.

What does a pharmacy pay for 30 generic 1 mg tablets?

About $0.735 on the NADAC benchmark ($0.025 per tablet times 30). That is acquisition cost, not a retail price: it excludes dispensing fees, discounts and rebates.

Cite this page

Figures are calculated from U.S. federal sources (see Data terms below) and rebuilt from dated snapshots. Cite it as:

OmniRx, "Clonazepam: FDA shortage, NADAC acquisition cost and Medicaid utilization", data as of October 2026. https://omnirx.org/drugs/clonazepam

Embed this chart

Free with attribution: paste this where you want the chart. It sizes itself to its content. A small "Powered by OmniRx" link stays in the widget; white-label licences remove it and add your own branding.

<iframe id="lx-drug-clonazepam" src="https://omnirx.org/embed/drug-clonazepam" width="100%" height="640" style="border:1px solid #e2e8f0;border-radius:10px" title="Clonazepam shortage and price timeline by omnirx.org" loading="lazy"></iframe>
<script>addEventListener('message',function(e){if(e.origin!=='https://omnirx.org')return;var d=e.data||{};if(d.type==='lx-height'&&d.slug==='drug-clonazepam'){var f=document.getElementById('lx-'+d.slug);if(f)f.height=d.height;}});</script>

Sources

Data terms. Every source above is published by a U.S. federal agency (CMS or FDA). CMS's data site labels its datasets inconsistently: of the 14 NADAC years, 5 carry the "public domain" label and 9 the "U.S. government works" label; of the 14 State Drug Utilization Data years, 6 carry the "public domain" label and 8 the "U.S. government works" label. We record each dataset's label verbatim and cite the source for every figure. Figures on this page are OmniRx calculations from those datasets, not statements by CMS or FDA, and no agency endorses this page.